|

Does an Early Invasive Strategy Improve 11-Year Survival in Stable Coronary Disease? 25.8% vs 26.9%

ByLife Choice Note

Short answer: In ISCHEMIA-EXTEND, published in JAMA on November 7, 2026, routinely adding early coronary angiography and revascularization to guideline-directed medical therapy did not significantly improve overall survival compared with starting with medical therapy and reserving invasive care for treatment failure. Eleven-year mortality was 25.8% versus 26.9%. This does not mean that stents or bypass surgery are never needed, and the result does not apply to a heart attack or uncontrolled angina.

Publication date: November 7, 2026 · Setting: 320 sites in 37 countries · Population: 5,179 adults with stable coronary disease and moderate or severe ischemia · Follow-up: median 9 years, maximum 13.4 years · Reviewed: November 9, 2026

What did the trial compare?

ISCHEMIA randomly assigned 5,179 people beginning in 2012. The initial invasive strategy combined guideline-directed medical therapy with routine coronary angiography and revascularization—PCI or bypass surgery—when feasible and appropriate. The initial conservative strategy used the same medical therapy, with angiography and revascularization reserved for failure of medical treatment or another clinical need.

This was a comparison of two management strategies, not a comparison of a stent with no treatment. Both groups received active risk-factor and medication management.

What happened to survival over 11 years?

Cumulative all-cause mortality at 11 years was 25.8% with the invasive strategy and 26.9% with the conservative strategy. The absolute difference was -1.0 percentage point, with a 95% confidence interval from -4.2 to 2.1 percentage points. The adjusted hazard ratio was 0.97 (95% CI, 0.86 to 1.09).

Restricted mean survival through 11 years differed by an estimated 14 days in favor of the invasive strategy, but the confidence interval ranged from 41 fewer to 70 more days. In a Bayesian analysis, the probability that the invasive strategy improved survival by more than 1 percentage point was 18%. The study therefore did not establish a meaningful overall survival advantage from routinely starting with invasive care.

What about cardiovascular deaths?

At 11 years, cardiovascular mortality was 15.8% with the invasive strategy and 17.1% with the conservative strategy. Noncardiovascular mortality was 9.1% and 8.1%, respectively. Uncertainty intervals for both comparisons included no difference. These cause-specific findings do not show that procedures caused cancer, infection, or another noncardiovascular death.

All-cause mortality is less vulnerable to disagreement about the cause of death and remains the central result: overall survival was similar between the two initial strategies.

Who was—and was not—included?

Participants had stable coronary disease, moderate or severe ischemia, and a left ventricular ejection fraction of at least 35%. Important exclusions included:

  • at least 50% left main coronary artery stenosis;
  • an acute coronary syndrome within the previous two months;
  • angina that was unacceptable despite treatment; and
  • an ejection fraction below 35%.

The findings should not be used to delay emergency evaluation for new chest pressure, sweating, severe breathlessness, or other possible heart attack symptoms. They also are not a reason to stop heart medication or cancel a recommended procedure without discussing the individual anatomy, symptoms, and risks with the treating clinician.

Symptoms and quality of life are a different outcome

This extended follow-up focused on mortality. During the original trial, people with angina had better symptom relief and quality of life for the first several years with the invasive strategy. A lack of proven survival benefit does not erase the value of relieving limiting chest pain. The decision can reasonably depend on symptom burden, coronary anatomy, heart function, procedural risk, and patient preferences.

Important limitations

  • The extended phase collected little information on nonfatal cardiovascular events, medication use, later procedures, angina, or quality of life after the original median 3.2-year follow-up.
  • Twenty-six percent of participants assigned to the conservative strategy underwent revascularization during the original phase when clinically needed.
  • Causes of death were no longer adjudicated by the independent committee during extended follow-up.
  • Coronary-anatomy subgroup analyses were limited because comparable imaging was not available for every participant.
  • PCI and medical therapy have advanced since enrollment began, so present-day absolute risks may differ.
  • The trial was international, but its percentages do not predict the outcome of an individual patient or every health system.

Questions for a clinical discussion

Useful questions include: Is the main goal longer survival, relief of angina, or both? Is there left main or extensive multivessel disease? Are symptoms controlled with medical therapy? What benefits, bleeding or kidney risks, and recovery burden are expected from angiography and revascularization in this specific case?

Primary sources checked

By: Life Choice Note · Independent personal health information. This article provides general information and does not determine diagnosis, medication changes, testing, or revascularization for an individual.

Related guides